ClinicalTrials.gg
CompletedNCT03594110Updated Jul 20, 2025Results posted

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

A Phase 3 interventional study of Empagliflozin and Matching placebo in Chronic Kidney Disease, sponsored by Boehringer Ingelheim. Completed at 240 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-20.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6,609
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing empagliflozin in Renal Insufficiency, Chronic — 6 open to participants now, 7 under way, 1 of them phase 3. empagliflozin · Renal Insufficiency, Chronic.

Enrollment
2nd of 20
6,609 · median 77
Started
2019
with 2 others
Phase 3
2 of 20
none open now
Registered
1st of 20
by date
Lead sponsor
4 of 20
Boehringer Ingelheim

Among the 20 studies testing empagliflozin in Renal Insufficiency, Chronic, this one is the 2nd largest by enrollment, is one of 3 that started in 2019, is one of 2 in phase 3, and was the 1st registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

6 of the 20 studies testing empagliflozin in Renal Insufficiency, Chronic are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing empagliflozin in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of standard of care in patients with pre-existing chronic kidney disease. After completion of the interventional part of the study (primary study completion) a subset of participants will be followed up in a post-trial observational (non-interventional) manner for cardio-renal outcomes (estimated study completion date).

03

Conditions studied

  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Age ≥18 years or at "full age" as required by local regulation
  • Evidence of chronic kidney disease at risk of kidney disease progression defined by at least 3 months before and at the time of Screening Visit

    • eGFR ≥20 to \<45 mL/min/1.73m² or
    • CKD-EPI eGFR ≥45 to \<90 mL/min/1.73m² with urinary albumin:creatinine ratio ≥200 mg/g (or protein:creatinine ratio ≥300 mg/g);
  • Clinically appropriate doses of single agent RAS-inhibition with either ACEi or ARB unless such treatment is either not tolerated or not indicated
  • A local Investigator judges that the participant neither requires empagliflozin (or any other SGLT-2 or SGLT-1/2 inhibitor), nor that such treatment is inappropriate;

Key Exclusion Criteria:

  • Currently receiving SGLT-2 or SGLT-1/2 inhibitor
  • Diabetes mellitus type 2 and prior atherosclerotic cardiovascular disease with an eGFR >60 mL/min/1.73m2 at Screening
  • Receiving combined ACEi and ARB treatment
  • Maintenance dialysis, functioning kidney transplant, or scheduled living donor transplant
  • Polycystic kidney disease
  • Previous or scheduled bariatric surgery
  • Ketoacidosis in the past 5 years
  • Symptomatic hypotension, or systolic blood pressure \<90 or >180 mmHg at Screening
  • or AST >3x at Screening
  • to empagliflozin or other SGLT-2 inhibitor
  • Any intravenous therapy in last 3 months; or anyone currently on >45 mg prednisolone (or equivalent)
  • Use of an medicinal product in the 30 days prior to Screening visit
  • Known to be poorly compliant with clinic visits or prescribed medication
  • Medical history that might limit the individual's ability to take trial treatments for the duration of the study (e.g. severe respiratory disease; history of cancer or evidence of spread within last 4 years, other than non-melanoma skin cancer; or recent history of alcohol or substance misuse)
  • Current pregnancy, lactation or women of (WOCBP), unless using highly-effective
  • Type 1 diabetes mellitus
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
6,609 participants (actual)

Study arms

  • Experimental
    Empagliflozin 10 mg

    Patients with evidence of chronic kidney disease (CKD) at risk of kidney disease progression, with or without diagnosed diabetes mellitus administered orally once daily 10 milligram (mg) film-coated tablets of empagliflozin.

    Drug: Empagliflozin

  • Placebo comparator
    Placebo

    Patients with evidence of chronic kidney disease (CKD) at risk of kidney disease progression, with or without diagnosed diabetes mellitus administered orally once daily film-coated tablets of placebo to match empagliflozin.

    Drug: Matching placebo

Interventions

  • Taken daily with or without food

  • DrugMatching placebo

    Taken daily with or without food

06

What researchers measure

Primary outcomes

  1. Interventional Part: Time to First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated')

    Time to first occurrence of kidney disease progression (KDP) or cardiovascular death is reported as incidence rate of first occurrence of KDP or adjudicated cardiovascular death. Incidence rate= (Number of patients who experienced the event of first occurrence of KDP or cardiovascular death)\*100/(patient years at risk (pt-yrs at risk). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25. Kidney disease progression was defined as: * end stage kidney disease (defined as the initiation of maintenance dialysis or receipt of a kidney transplant) OR * a sustained decline in estimated glomerular filtration rate (eGFR) to \<10 mL/min/1.73m\^2 OR * renal death OR * a sustained decline of ≥40% in eGFR from randomisation.

    Time frame: From the day of randomisation to the day of the final follow-up visit in the interventional part of the trial, up to 1136 days.

  2. Overall Study: Time to the First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated')

    Time to first occurrence of kidney disease progression (KDP) or cardiovascular death is reported as incidence of progression of kidney disease or death from cardiovascular causes in the interventional part of the trial and in the post-trial follow-up (non-interventional part). Incidence rate= (Number of patients who experienced the event of first occurrence of KDP or cardiovascular death)\*100/(patient years at risk (pt-yrs at risk). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25. Kidney disease progression was defined as: * a sustained decline in eGFR to less than 10 mL/min/1.73m\^2 OR * renal death OR * sustained decline of more than 40% in eGFR from randomization.

    Time frame: From the day of randomization in the interventional part of the trial until the individual day of end of study in the non-interventional part of the trial. Up to 1869 days.

Secondary outcomes

  1. Key Secondary Endpoint: Interventional Part - Time to First Hospitalization for Heart Failure ('as Adjudicated') or Cardiovascular Death ('as Adjudicated')

    Time to first hospitalization for heart failure ('as adjudicated') or cardiovascular death ('as adjudicated') is reported as incidence rate of first hospitalization for heart failure or cardiovascular death. Incidence rate= (Number of patients who experienced the event of first hospitalization for heart failure or cardiovascular death) \*100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25.

    Time frame: From the day of randomisation to the day of the final follow-up visit of the interventional part, up to 1140 days.

  2. Key Secondary Endpoint: Interventional Part - Time to Occurrences of All-cause Hospitalizations (First and Recurrent Combined)

    Time to occurrences of all-cause hospitalizations is reported as total number of all-cause hospitalizations (first and recurrent combined).

    Time frame: From the day of randomisation to the day of the final follow-up visit of the interventional part, up to 1140 days.

  3. Key Secondary Endpoint: Interventional Part - Time to Death From Any Cause ('as Adjudicated')

    Time to death from any cause is reported as incidence rate of death from any cause. Incidence rate of death from any cause = (Number of patients who experienced the event of death from any cause) \* 100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25.

    Time frame: From the day of randomisation to the day of the final follow-up visit in the interventional part of the trial, up to 1140 days.

  4. Interventional Part: Time to First Occurrence of Kidney Disease Progression

    Time to first occurrence of kidney disease progression (KDP) is reported as incidence rate of first occurrence of kidney disease progression. Incidence rate of first occurrence of kidney disease progression= (Number of patients who experienced the event of first occurrence of kidney disease progression) \*100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25. Kidney disease progression was defined as: * end stage kidney disease (defined as the initiation of maintenance dialysis or receipt of a kidney transplant) OR * a sustained decline in estimated glomerular filtration rate (eGFR) to \<10 mL/min/1.73m\^2 OR * renal death OR * a sustained decline of ≥40% in eGFR from randomisation).

    Time frame: From the day of randomisation to the day of the final follow-up visit of the interventional part, up to 1136 days.

  5. Interventional Part: Time to Cardiovascular Death ('as Adjudicated')

    Time to cardiovascular death ('as adjudicated') is reported as incidence rate of cardiovascular death. Incidence rate of cardiovascular death= (Number of patients who experienced the event of cardiovascular death) \*100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25.

    Time frame: From the day of randomisation to the day of the final follow-up visit of the interventional part, up to 1140 days.

  6. Interventional Part: Time to First Occurrence Cardiovascular Death ('as Adjudicated') or End Stage Kidney Disease (ESKD)

    Time to first occurrence of cardiovascular death ('as adjudicated') or end stage kidney disease is reported as incidence rate of first occurrence of cardiovascular death or end stage kidney disease (ESKD). Incidence rate of first occurrence cardiovascular death or end stage kidney disease (ESKD)= (Number of patients who experienced the event of first occurrence of cardiovascular death or end stage kidney disease (ESKD)) \*100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25. ESKD was defined as the initiation of maintenance dialysis or receipt of a kidney transplant.

    Time frame: From the day of randomization to the day of the final follow-up visit in the interventional part of the trial, up to 1140 days.

  7. Overall Study: Time to First Occurrence of Kidney Disease Progression

    The time to first occurrence of kidney disease progression in the interventional part of the trial and in the post-trial follow-up (non-interventional part) is reported as the incidence rate of first occurrence of kidney disease progression. Incidence rate of first occurrence of kidney disease progression= (Number of patients who experienced the event of first occurrence of kidney disease progression) \*100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25. Kidney disease progression was defined as: * end stage kidney disease (defined as the initiation of maintenance dialysis or receipt of a kidney transplant) OR * a sustained decline in estimated glomerular filtration rate (eGFR) to \<10 mL/min/1.73m\^2 OR * renal death OR * a sustained decline of ≥40% in eGFR from randomisation.

    Time frame: From the day of randomization in the interventional part of the trial until the individual day of end of study in the non-interventional part of the trial. Up to 1869 days.

  8. Overall Study: Time to First Occurrence of Death From Any Cause or ESKD

    Time to first occurrence of death from any cause or end stage kidney disease (ESKD) in the interventional part of the trial and in the post-trial follow-up (non-interventional part) is reported as incidence rate of first occurrence of death from any cause or ESKD. Incidence rate of first occurrence of death from any cause or end stage kidney disease (ESKD)= (Number of patients who experienced the event of first occurrence of death any cause or end stage kidney disease (ESKD)) \*100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25. ESKD was defined as the initiation of maintenance dialysis or receipt of a kidney transplant.

    Time frame: From the day of randomization in the interventional part of the trial until the individual day of end of study in the non-interventional part of the trial. Up to 1869 days.

  9. Overall Study: Time to First Occurrence of ESKD

    Time to first occurrence of end stage kidney disease (ESKD) in the interventional part of the trial and in the post-trial follow-up (non-interventional part) is reported as incidence rate of first occurrence of ESKD. Incidence rate of first occurrence of end stage kidney disease (ESKD)= (Number of patients who experienced the event of first occurrence of ESKD) \*100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25. ESKD was defined as the initiation of maintenance dialysis or receipt of a kidney transplant.

    Time frame: From the day of randomization in the interventional part of the trial until the individual day of end of study in the non-interventional part of the trial. Up to 1869 days.

  10. Body Composition Measurement Sub-study: Mean Absolute Fluid Overload, Averaged Over Time

    Mean absolute fluid overload averaged over time in the body composition measurement sub-study. Fluid overload or overhydration was measured using bioimpedance spectroscopy which derives the amount of water in liters (L) in the adipose tissue and lean mass tissues and computed as the difference between expected (based upon weight and body composition) versus measured extracellular water volume, with positive values representing excess fluid. A mixed model of repeated measures (MMRM) with terms for baseline, age, sex, screening diabetes status, local screening eGFR, local screening UACR, treatment, treatment-by-time interaction and baseline-by-time interaction was used for the analysis. The weighted mean of the values at 2 and 18 months.

    Time frame: MMRM included measurements at baseline, 2 months, and 18 months.

  11. Magnetic Resonance Imaging Sub-study: Kidney Cortical T1 Mapping as Measured by Modified Look-Locker Inversion Recovery (MOLLI) at 18 Months

    Kidney cortical T1 mapping using the modified Look-Locker inversion recovery (MOLLI) measured by magnetic resonance imaging (MRI) in the placebo and empagliflozin groups. A linear regression with terms for age, sex, screening diabetes status, local screening eGFR, local screening UACR was used in the analysis.

    Time frame: At 18 months.

07

Results

Posted Jul 27, 2023

Participant flow

Trial with a interventional and a non-interventional part (post-trial follow-up). Interventional part: event-driven (ca. 1070 primary outcome events). Alongside the trial, a fraction of patients randomized in the interventional part gave consent to two sub-studies: body composition measurement and magnetic resonance imaging. Non-interventional part: patients who gave consent were observed for ca. 2 years.

Interventional Part
Participant flow — Interventional Part
MilestonePlaceboEmpagliflozin 10 mg
Started33053304
Treated33053304
Body composition measurement (bcm) sub-study328332
Magnetic resonance imaging (mri) sub-study7993
Completed24572549
Not completed848755
Withdrew: Participant concerned about study treatment2328
Withdrew: Doctor advice3840
Withdrew: Participants' wish8968
Withdrew: Adverse event-non-fatal events119116
Withdrew: Study drug stopped, reason missing336294
Withdrew: Cannot attend clinic because of personal problems816
Withdrew: Cannot attend clinic because moving out of the area159
Withdrew: Contraindicated drug started3218
Withdrew: Other reasons (include any category with a frequency <20 patients in total)5845
Withdrew: Adverse event-serious fatal events130121
Non-interventional Part
Participant flow — Non-interventional Part
MilestonePlaceboEmpagliflozin 10 mg
Started24192472
Completed23712427
Not completed4845
Withdrew: Withdrawal by subject34
Withdrew: Lost to follow-up4541

Outcome measures

PrimaryInterventional Part: Time to First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated')

Time to first occurrence of kidney disease progression (KDP) or cardiovascular death is reported as incidence rate of first occurrence of KDP or adjudicated cardiovascular death. Incidence rate= (Number of patients who experienced the event of first occurrence of KDP or cardiovascular death)\*100/(patient years at risk (pt-yrs at risk). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25. Kidney disease progression was defined as: * end stage kidney disease (defined as the initiation of maintenance dialysis or receipt of a kidney transplant) OR * a sustained decline in estimated glomerular filtration rate (eGFR) to \<10 mL/min/1.73m\^2 OR * renal death OR * a sustained decline of ≥40% in eGFR from randomisation.

Time frame:
From the day of randomisation to the day of the final follow-up visit in the interventional part of the trial, up to 1136 days.
Reported as:
Number · patients with events/100 pt-yrs at risk
Interventional Part: Time to First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated')
patients with events/100 pt-yrs at riskPlaceboEmpagliflozin 10 mg
Interventional Part: Time to First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated')8.96 (8.23 to 9.72)6.85 (6.22 to 7.51)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 0.72 · 99.83% CI 0.59 to 0.89Comparison vs. Placebo
SecondaryKey Secondary Endpoint: Interventional Part - Time to First Hospitalization for Heart Failure ('as Adjudicated') or Cardiovascular Death ('as Adjudicated')

Time to first hospitalization for heart failure ('as adjudicated') or cardiovascular death ('as adjudicated') is reported as incidence rate of first hospitalization for heart failure or cardiovascular death. Incidence rate= (Number of patients who experienced the event of first hospitalization for heart failure or cardiovascular death) \*100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25.

Time frame:
From the day of randomisation to the day of the final follow-up visit of the interventional part, up to 1140 days.
Reported as:
Number · patients with events/100 pt-yrs at risk
Key Secondary Endpoint: Interventional Part - Time to First Hospitalization for Heart Failure ('as Adjudicated') or Cardiovascular Death ('as Adjudicated')
patients with events/100 pt-yrs at riskPlaceboEmpagliflozin 10 mg
Key Secondary Endpoint: Interventional Part - Time to First Hospitalization for Heart Failure ('as Adjudicated') or Cardiovascular Death ('as Adjudicated')2.39 (2.03 to 2.78)2.04 (1.70 to 2.40)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Regression, Cox · p = 0.1363 · Hazard ratio (hr): 0.84 · 98.55% CI 0.63 to 1.12Comparison vs. Placebo
SecondaryKey Secondary Endpoint: Interventional Part - Time to Occurrences of All-cause Hospitalizations (First and Recurrent Combined)

Time to occurrences of all-cause hospitalizations is reported as total number of all-cause hospitalizations (first and recurrent combined).

Time frame:
From the day of randomisation to the day of the final follow-up visit of the interventional part, up to 1140 days.
Reported as:
Number · events (first and recurrent)
Key Secondary Endpoint: Interventional Part - Time to Occurrences of All-cause Hospitalizations (First and Recurrent Combined)
events (first and recurrent)PlaceboEmpagliflozin 10 mg
Key Secondary Endpoint: Interventional Part - Time to Occurrences of All-cause Hospitalizations (First and Recurrent Combined)18951612
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Joint frailty model · p = 0.0022 · Hazard ratio (hr): 0.86 · 99.03% CI 0.76 to 0.98Comparison vs. Placebo
SecondaryKey Secondary Endpoint: Interventional Part - Time to Death From Any Cause ('as Adjudicated')

Time to death from any cause is reported as incidence rate of death from any cause. Incidence rate of death from any cause = (Number of patients who experienced the event of death from any cause) \* 100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25.

Time frame:
From the day of randomisation to the day of the final follow-up visit in the interventional part of the trial, up to 1140 days.
Reported as:
Number · patients with events/100 pt-yrs at risk
Key Secondary Endpoint: Interventional Part - Time to Death From Any Cause ('as Adjudicated')
patients with events/100 pt-yrs at riskPlaceboEmpagliflozin 10 mg
Key Secondary Endpoint: Interventional Part - Time to Death From Any Cause ('as Adjudicated')2.59 (2.21 to 3.00)2.29 (1.94 to 2.68)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Regression, Cox · p = 0.2122 · Hazard ratio (hr): 0.87 · 97.1% CI 0.68 to 1.11Comparison vs. Placebo
SecondaryInterventional Part: Time to First Occurrence of Kidney Disease Progression

Time to first occurrence of kidney disease progression (KDP) is reported as incidence rate of first occurrence of kidney disease progression. Incidence rate of first occurrence of kidney disease progression= (Number of patients who experienced the event of first occurrence of kidney disease progression) \*100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25. Kidney disease progression was defined as: * end stage kidney disease (defined as the initiation of maintenance dialysis or receipt of a kidney transplant) OR * a sustained decline in estimated glomerular filtration rate (eGFR) to \<10 mL/min/1.73m\^2 OR * renal death OR * a sustained decline of ≥40% in eGFR from randomisation).

Time frame:
From the day of randomisation to the day of the final follow-up visit of the interventional part, up to 1136 days.
Reported as:
Number · patients with events/100 pt-yrs at risk
Interventional Part: Time to First Occurrence of Kidney Disease Progression
patients with events/100 pt-yrs at riskPlaceboEmpagliflozin 10 mg
Interventional Part: Time to First Occurrence of Kidney Disease Progression8.09 (7.40 to 8.81)6.09 (5.50 to 6.72)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 0.71 · 95% CI 0.62 to 0.81Comparison vs. Placebo
SecondaryInterventional Part: Time to Cardiovascular Death ('as Adjudicated')

Time to cardiovascular death ('as adjudicated') is reported as incidence rate of cardiovascular death. Incidence rate of cardiovascular death= (Number of patients who experienced the event of cardiovascular death) \*100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25.

Time frame:
From the day of randomisation to the day of the final follow-up visit of the interventional part, up to 1140 days.
Reported as:
Number · patients with events/100 pt-yrs at risk
Interventional Part: Time to Cardiovascular Death ('as Adjudicated')
patients with events/100 pt-yrs at riskPlaceboEmpagliflozin 10 mg
Interventional Part: Time to Cardiovascular Death ('as Adjudicated')1.08 (0.84 to 1.35)0.91 (0.69 to 1.15)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Regression, Cox · p = 0.2932 · Hazard ratio (hr): 0.83 · 95% CI 0.59 to 1.17Comparison vs. Placebo
SecondaryInterventional Part: Time to First Occurrence Cardiovascular Death ('as Adjudicated') or End Stage Kidney Disease (ESKD)

Time to first occurrence of cardiovascular death ('as adjudicated') or end stage kidney disease is reported as incidence rate of first occurrence of cardiovascular death or end stage kidney disease (ESKD). Incidence rate of first occurrence cardiovascular death or end stage kidney disease (ESKD)= (Number of patients who experienced the event of first occurrence of cardiovascular death or end stage kidney disease (ESKD)) \*100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25. ESKD was defined as the initiation of maintenance dialysis or receipt of a kidney transplant.

Time frame:
From the day of randomization to the day of the final follow-up visit in the interventional part of the trial, up to 1140 days.
Reported as:
Number · patients with events/100 pt-yrs at risk
Interventional Part: Time to First Occurrence Cardiovascular Death ('as Adjudicated') or End Stage Kidney Disease (ESKD)
patients with events/100 pt-yrs at riskPlaceboEmpagliflozin 10 mg
Interventional Part: Time to First Occurrence Cardiovascular Death ('as Adjudicated') or End Stage Kidney Disease (ESKD)3.45 (3.01 to 3.92)2.55 (2.18 to 2.96)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Regression, Cox · p = 0.0017 · Hazard ratio (hr): 0.72 · 95% CI 0.59 to 0.89Comparison vs. Placebo
PrimaryOverall Study: Time to the First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated')

Time to first occurrence of kidney disease progression (KDP) or cardiovascular death is reported as incidence of progression of kidney disease or death from cardiovascular causes in the interventional part of the trial and in the post-trial follow-up (non-interventional part). Incidence rate= (Number of patients who experienced the event of first occurrence of KDP or cardiovascular death)\*100/(patient years at risk (pt-yrs at risk). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25. Kidney disease progression was defined as: * a sustained decline in eGFR to less than 10 mL/min/1.73m\^2 OR * renal death OR * sustained decline of more than 40% in eGFR from randomization.

Time frame:
From the day of randomization in the interventional part of the trial until the individual day of end of study in the non-interventional part of the trial. Up to 1869 days.
Reported as:
Number · patients with events/100 pt-yrs at risk
Overall Study: Time to the First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated')
patients with events/100 pt-yrs at riskPlaceboEmpagliflozin 10 mg
Overall Study: Time to the First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated')9.99 (9.38 to 10.62)8.36 (7.81 to 8.93)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Hazard ratio (hr): 0.79 · 95% CI 0.72 to 0.87Comparison vs. Placebo
SecondaryOverall Study: Time to First Occurrence of Kidney Disease Progression

The time to first occurrence of kidney disease progression in the interventional part of the trial and in the post-trial follow-up (non-interventional part) is reported as the incidence rate of first occurrence of kidney disease progression. Incidence rate of first occurrence of kidney disease progression= (Number of patients who experienced the event of first occurrence of kidney disease progression) \*100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25. Kidney disease progression was defined as: * end stage kidney disease (defined as the initiation of maintenance dialysis or receipt of a kidney transplant) OR * a sustained decline in estimated glomerular filtration rate (eGFR) to \<10 mL/min/1.73m\^2 OR * renal death OR * a sustained decline of ≥40% in eGFR from randomisation.

Time frame:
From the day of randomization in the interventional part of the trial until the individual day of end of study in the non-interventional part of the trial. Up to 1869 days.
Reported as:
Number · patients with events/100 pt-yrs at risk
Overall Study: Time to First Occurrence of Kidney Disease Progression
patients with events/100 pt-yrs at riskPlaceboEmpagliflozin 10 mg
Overall Study: Time to First Occurrence of Kidney Disease Progression8.95 (8.37 to 9.55)7.52 (7.00 to 8.06)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Hazard ratio (hr): 0.79 · 95% CI 0.72 to 0.87Comparison vs. Placebo
SecondaryOverall Study: Time to First Occurrence of Death From Any Cause or ESKD

Time to first occurrence of death from any cause or end stage kidney disease (ESKD) in the interventional part of the trial and in the post-trial follow-up (non-interventional part) is reported as incidence rate of first occurrence of death from any cause or ESKD. Incidence rate of first occurrence of death from any cause or end stage kidney disease (ESKD)= (Number of patients who experienced the event of first occurrence of death any cause or end stage kidney disease (ESKD)) \*100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25. ESKD was defined as the initiation of maintenance dialysis or receipt of a kidney transplant.

Time frame:
From the day of randomization in the interventional part of the trial until the individual day of end of study in the non-interventional part of the trial. Up to 1869 days.
Reported as:
Number · patients with events/100 pt-yrs at risk
Overall Study: Time to First Occurrence of Death From Any Cause or ESKD
patients with events/100 pt-yrs at riskPlaceboEmpagliflozin 10 mg
Overall Study: Time to First Occurrence of Death From Any Cause or ESKD6.08 (5.62 to 6.55)5.13 (4.71 to 5.56)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Hazard ratio (hr): 0.81 · 95% CI 0.72 to 0.90Comparison vs. Placebo
SecondaryOverall Study: Time to First Occurrence of ESKD

Time to first occurrence of end stage kidney disease (ESKD) in the interventional part of the trial and in the post-trial follow-up (non-interventional part) is reported as incidence rate of first occurrence of ESKD. Incidence rate of first occurrence of end stage kidney disease (ESKD)= (Number of patients who experienced the event of first occurrence of ESKD) \*100/(patient years at risk (pt-yrs at risk)). pt-yrs at risk= sum of time at risk \[days\] over all patients in a treatment group / 365.25. ESKD was defined as the initiation of maintenance dialysis or receipt of a kidney transplant.

Time frame:
From the day of randomization in the interventional part of the trial until the individual day of end of study in the non-interventional part of the trial. Up to 1869 days.
Reported as:
Number · patients with events/100 pt-yrs at risk
Overall Study: Time to First Occurrence of ESKD
patients with events/100 pt-yrs at riskPlaceboEmpagliflozin 10 mg
Overall Study: Time to First Occurrence of ESKD3.49 (3.14 to 3.85)2.72 (2.41 to 3.03)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Hazard ratio (hr): 0.74 · 95% CI 0.64 to 0.87Comparison vs. Placebo
SecondaryBody Composition Measurement Sub-study: Mean Absolute Fluid Overload, Averaged Over Time

Mean absolute fluid overload averaged over time in the body composition measurement sub-study. Fluid overload or overhydration was measured using bioimpedance spectroscopy which derives the amount of water in liters (L) in the adipose tissue and lean mass tissues and computed as the difference between expected (based upon weight and body composition) versus measured extracellular water volume, with positive values representing excess fluid. A mixed model of repeated measures (MMRM) with terms for baseline, age, sex, screening diabetes status, local screening eGFR, local screening UACR, treatment, treatment-by-time interaction and baseline-by-time interaction was used for the analysis. The weighted mean of the values at 2 and 18 months.

Time frame:
MMRM included measurements at baseline, 2 months, and 18 months.
Reported as:
Least squares mean · Liters
Body Composition Measurement Sub-study: Mean Absolute Fluid Overload, Averaged Over Time
LitersPlaceboEmpagliflozin 10 mg
Body Composition Measurement Sub-study: Mean Absolute Fluid Overload, Averaged Over Time0.34 ± 0.050.10 ± 0.05
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -0.24 · 95% CI -0.38 to -0.11\[Comparator\] - \[Placebo\]
SecondaryMagnetic Resonance Imaging Sub-study: Kidney Cortical T1 Mapping as Measured by Modified Look-Locker Inversion Recovery (MOLLI) at 18 Months

Kidney cortical T1 mapping using the modified Look-Locker inversion recovery (MOLLI) measured by magnetic resonance imaging (MRI) in the placebo and empagliflozin groups. A linear regression with terms for age, sex, screening diabetes status, local screening eGFR, local screening UACR was used in the analysis.

Time frame:
At 18 months.
Reported as:
Least squares mean · milliseconds
Magnetic Resonance Imaging Sub-study: Kidney Cortical T1 Mapping as Measured by Modified Look-Locker Inversion Recovery (MOLLI) at 18 Months
millisecondsPlaceboEmpagliflozin 10 mg
Magnetic Resonance Imaging Sub-study: Kidney Cortical T1 Mapping as Measured by Modified Look-Locker Inversion Recovery (MOLLI) at 18 Months1634 ± 111622 ± 10
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Regression, Linear · p = 0.41 · Mean difference (net): -12 · 95% CI -42 to 17\[Comparator\]-\[Placebo\]

Adverse events

Collected over All-cause Mortality: From randomisation until end of study, up to 1869 days. Adverse events reporting: From randomisation until 7 days (Residual Effect Period) after the last drug intake, up to 1147 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo353/3,305 (10.7%)1,167/3,305 (35.3%)262/3,305 (7.9%)
Empagliflozin 10 mg314/3,304 (9.5%)1,089/3,304 (33%)228/3,304 (6.9%)
Most frequent serious events
Showing 10 of 873
Most frequent serious events
EventPlaceboEmpagliflozin 10 mg
Acute kidney injuryRenal and urinary disorders117/330593/3304
Corona virus infectionInfections and infestations107/330598/3304
Blood potassium increasedInvestigations87/330576/3304
Blood creatinine increasedInvestigations56/330543/3304
Ischaemic cardiomyopathyCardiac disorders45/330533/3304
Cardiac failureCardiac disorders44/330541/3304
PneumoniaInfections and infestations42/330539/3304
Myocardial infarctionCardiac disorders31/330539/3304
End stage renal diseaseRenal and urinary disorders27/330535/3304
Ischaemic strokeNervous system disorders34/330530/3304
Most frequent other events
Most frequent other events
EventPlaceboEmpagliflozin 10 mg
GoutMetabolism and nutrition disorders262/3305228/3304

Baseline characteristics

Randomised set (RS) included all randomised participants, whether treated or not.

Age, Continuous
Age, Continuous(Years)PlaceboEmpagliflozin 10 mgTotal
Mean63.3 ± 13.963.4 ± 13.963.3 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEmpagliflozin 10 mgTotal
Female109510972192
Male221022074417
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboEmpagliflozin 10 mgTotal
Hispanic or Latino119103222
Not Hispanic or Latino7237081431
Unknown or Not Reported246324934956
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboEmpagliflozin 10 mgTotal
White192019393859
Black/ African-American134128262
Asian119911942393
Other including mixed race524395
08

Study locations

240 sites
  • Nephrology Consultants, LLC
    Huntsville, Alabama 35805, United States
  • Aventiv Research, Inc
    Mesa, Arizona 85210, United States
  • Southern California Permanente Medical Group
    San Diego, California 92123, United States
  • University of California Los Angeles
    Sylmar, California 91342, United States
  • University of California Los Angeles
    Torrance, California 90502, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • Chase Medical Research, LLC
    Thomaston, Connecticut 06787, United States
  • Midland Florida Clinical Reearch Center, LLC
    DeLand, Florida 32720, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32216, United States
  • East Coast Clinical Research, Inc
    Lake City, Florida 32055, United States
  • Total Research Group, LLC
    Miami, Florida 33126, United States
  • Hanson Clinical Research Center, Inc.
    Port Charlotte, Florida 33952, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • The Jones Center for Diabetes and Endocrine Wellness
    Macon, Georgia 31210, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Saint Elizabeth Healthcare
    Covington, Kentucky 41011, United States
  • Lexington VA Health Care System - Troy Bowling Campus
    Lexington, Kentucky 40502, United States
  • Medstar Health Research Institute
    Baltimore, Maryland 21239, United States
  • Kidney Care and Transplant Services of New England, PC
    West Springfield, Massachusetts 01089, United States
  • Saint Clair Specialty Physicians
    Roseville, Michigan 48066, United States
  • Clinical Research Consultants, LLC
    Kansas City, Missouri 64111, United States
  • VA Southern Nevada Healthcare System
    North Las Vegas, Nevada 89086, United States
  • Seacoast Kidney and Hypertension Specialists
    Portsmouth, New Hampshire 03801, United States
  • SUNY Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Mountain Kidney and Hypertension Associates, PA
    Asheville, North Carolina 28801, United States
  • The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Brookview Hills Research Associates LLC
    Winston-Salem, North Carolina 27103, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19114, United States
  • Carolina Diabetes & Kidney Center
    Sumter, South Carolina 29150, United States
  • Regional Health Clinical Research
    Rapid City, South Dakota 57701, United States
  • Research Institute of Dallas
    Dallas, Texas 75231, United States
  • Renal Disease Research Institute
    Dallas, Texas 75246, United States
  • Academy Of Diabetes, Thyroid And Endocrine, PA
    El Paso, Texas 79935, United States
  • Pioneer Research Solutions, Inc.
    Houston, Texas 77099, United States
  • P&I Clinical Research, LLC
    Lufkin, Texas 75904, United States
  • Texas Institute for Kidney and Endocrine Disorders
    Lufkin, Texas 75904, United States
  • Clinical Advancement Center PLLC
    San Antonio, Texas 78212, United States
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • University of Utah Health Sciences Center
    Salt Lake City, Utah 84108, United States
  • Salem VA Medical Center
    Salem, Virginia 24153, United States
  • Providence Medical Research Center
    Spokane, Washington 99204, United States
  • Kelowna General Hospital
    Kelowna, British Columbia V1Y 1T2, Canada
  • Kidney Care Centre - Surrey
    Surrey, British Columbia V3T 5H6, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • St. Paul's Hospital
    Vancouver, British Columbia V6Z 1Y6, Canada
  • LMC Clinical Research Inc. (Brampton)
    Brampton, Ontario L6S 0C6, Canada
  • Cambridge Cardiac Care Centre
    Cambridge, Ontario N1R 6V6, Canada
  • LMC Clinical Research Inc. (Thornhill)
    Concord, Ontario L4K 4M2, Canada
  • LMC Endocrinology Centres (Etobicoke) Ltd.
    Etobicoke, Ontario M9R 4E1, Canada
  • London Health Science Centre, University Campus
    London, Ontario N6A 4G5, Canada
  • LMC Clinical Research Inc. (Ottawa)
    Nepean, Ontario K2J 0V2, Canada
  • Lakeridge Health Oshawa
    Oshawa, Ontario L1G 2B9, Canada
  • LMC Clinical Research Inc. (Bayview)
    Toronto, Ontario M4G 3E8, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
  • Fadia El Boreky Medicine Professional
    Waterloo, Ontario N2J 1C4, Canada
  • Clinical Research Solutions Inc.
    Waterloo, Ontario N2J 3Z4, Canada
  • Montreal Clinical Research Institute (IRCM)
    Montreal, Quebec H2W 1R7, Canada
  • Hôpital du Sacré-Coeur de Montréal
    Montreal, Quebec H4J 1C5, Canada
  • CHUS Hopital Fleurimont
    Sherbrooke, Quebec J1H 5N4, Canada
  • CHU de Quebec-Universite Laval Research Centre
    Québec, G1R 2J6, Canada
  • IUCPQ (Laval University)
    Québec, G1V 4G5, Canada
  • Beijing AnZhen Hospital
    Beijing, 100029, China
  • Cardiovascular Institute and Fu Wai Hospital
    Beijing, 100037, China
  • Xiangya Hospital, Central South University
    Changsha, 410008, China
  • Xinqiao Hospital
    Chongqing, 400037, China
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, 310000, China
  • Jinzhou Central Hospital
    Jinzhou, 121000, China
  • Jinling Hospital
    Nanjing, 210002, China
  • Shanghai Fifth People's Hospital affiliated to Fudan University
    Shanghai, 200240, China
  • Shenzhen People's Hospital
    Shenzhen, 518020, China
  • Huazhong University of Science and Technology Union Shenzhen Hospital
    Shenzhen, 518052, China
  • People's Hospital of Sichuan Province
    Sichuan, 610031, China
  • SuZhou Kowloon Hospital
    Suzhou, 215000, China
  • The Central Hospital of Wuhan
    Wuhan, 430014, China
  • Wuhan Fourth Hospital
    Wuhan, 430033, China
  • Henan Provincial People's Hospital
    Zhengzhou, 450003, China
  • Zhuzhou Central Hospital
    Zhuzhou, 412000, China
  • Zhuzhou Central Hospital
    Zhuzhou, 412007, China
  • Studienzentrum Aschaffenburg
    Aschaffenburg, 63739, Germany
  • Universitätsklinikum Augsburg
    Augsburg, 86156, Germany
  • Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen
    Bad Oeynhausen, 32545, Germany
  • Vivantes Netzwerk für Gesundheit GmbH
    Berlin, 12351, Germany
  • Ärztezentrum Helle Mitte
    Berlin, 12627, Germany
  • Klinikum Bielefeld gGmbH
    Bielefeld, 33604, Germany
  • Städtisches Klinikum Braunschweig gGmbH
    Braunschweig, 38126, Germany
  • Universitätsklinikum Carl Gustav Carus Dresden
    Dresden, 01307, Germany
  • Universitätsklinikum Düsseldorf
    Düsseldorf, 40225, Germany
  • Agaplesion Markus Krankenhaus
    Frankfurt, 60431, Germany
  • ClinPhenomics GmbH & Co KG, Frankfurt
    Frankfurt, 60594, Germany
  • Nierenzentrum Freiburg
    Freiburg im Breisgau, 79100, Germany
  • Nephrologisches Zentrum Göttingen
    Göttingen, 37075, Germany
  • Universitätsklinikum Halle/S.
    Halle, 06120, Germany
  • Zentrum für Nieren-, Hochdruck und Stoffwechselerkrankungen
    Hanover, 30453, Germany
  • Medizinische Hochschule Hannover
    Hanover, 30625, Germany

Showing the first 100 of 240 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Mottl A, Scott C, Green JB, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rosenstock J, Rossing P, Li L, Li N, Vaduganathan M, Agarwal R; CONFIDENCE Trial Investigators. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. J Am Soc Nephrol. 2026 Apr 1;37(4):764-776. doi: 10.1681/ASN.0000000928. Epub 2025 Nov 6. PubMed 41196655 ↗
  • Uster A, Desai N, Navaneethan SD, Pfarr E, Mazo AR. Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial. Clin Ther. 2025 Dec;47(12):1091-1096. doi: 10.1016/j.clinthera.2025.09.005. Epub 2025 Oct 4. PubMed 41047325 ↗
  • Zhou J, Williams C, Staplin N, Judge PK, Mayne KJ, Agrawal N, Arimoto R, Green JB, Cherney DZI, Tuttle KR, Leal J, Clarke P, Emberson JR, Preiss D, Wanner C, Landray MJ, Baigent C, Haynes R, Herrington WG, Mihaylova B; EMPA-KIDNEY Collaborative Group. Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial. EClinicalMedicine. 2025 Jul 8;85:103338. doi: 10.1016/j.eclinm.2025.103338. eCollection 2025 Jul. PubMed 40686671 ↗
  • Oshima M, Buizen L, Jongs N, Levin A, Chertow GM, Wheeler DC, Heerspink HJL, Arnott C, Jardine MJ, Mahaffey KW, Pollock C, Herrington WG, Perkovic V, Neuen BL. Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials. Clin J Am Soc Nephrol. 2025 Jul 14;20(9):1206-1214. doi: 10.2215/CJN.0000000771. PubMed 40658498 ↗
  • Mayne KJ, Sardell RJ, Staplin N, Judge PK, Zhu D, Sammons E, Cherney DZI, Cheung AK, Maggioni AP, Nangaku M, Rossello X, Tuttle KR, Ihara K, Iwata T, Wanner C, Emberson J, Preiss D, Landray MJ, Baigent C, Haynes R, Herrington WG; EMPA-KIDNEY Collaborative Group. Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial. Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1119-1129. doi: 10.2215/CJN.0000000000000498. Epub 2024 Jun 27. PubMed 40179340 ↗
  • EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Zhu D, Dayanandan R, Arimoto R, Mayne KJ, Ng SYA, Sammons E, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney DZI, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Brueckmann M, Landray MJ, Baigent C, Haynes R; EMPA-KIDNEY Collaborative Group. Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2025 Feb 20;392(8):777-787. doi: 10.1056/NEJMoa2409183. Epub 2024 Oct 25. PubMed 39453837 ↗
  • Natale P, Tunnicliffe DJ, Toyama T, Palmer SC, Saglimbene VM, Ruospo M, Gargano L, Stallone G, Gesualdo L, Strippoli GF. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2. PubMed 38770818 ↗
  • Fletcher RA, Herrington WG, Agarwal R, Mayne KJ, Arnott C, Jardine MJ, Mahaffey KW, Perkovic V, Staplin N, Wheeler DC, Chertow GM, Heerspink HJL, Neuen BL. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials. Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1180-1182. doi: 10.2215/CJN.0000000000000470. Epub 2024 Apr 16. PubMed 38622766 ↗
  • Mayne KJ, Staplin N, Keane DF, Wanner C, Brenner S, Cejka V, Stegbauer J, Judge PK, Preiss D, Emberson J, Trinca D, Dayanandan R, Lee R, Nolan J, Omata A, Green JB, Cherney DZI, Hooi LS, Pontremoli R, Tuttle KR, Lees JS, Mark PB, Davies SJ, Hauske SJ, Steubl D, Bruckmann M, Landray MJ, Baigent C, Haynes R, Herrington WG; EMPA-KIDNEY Collaborative Group. Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD. J Am Soc Nephrol. 2024 Feb 1;35(2):202-215. doi: 10.1681/ASN.0000000000000271. Epub 2023 Dec 12. PubMed 38082486 ↗
  • EMPA-KIDNEY Collaborative Group. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024 Jan;12(1):51-60. doi: 10.1016/S2213-8587(23)00322-4. Epub 2023 Dec 4. PubMed 38061372 ↗
  • EMPA-KIDNEY Collaborative Group. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes Endocrinol. 2024 Jan;12(1):39-50. doi: 10.1016/S2213-8587(23)00321-2. Epub 2023 Dec 4. PubMed 38061371 ↗
  • The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. PubMed 36331190 ↗
  • Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, Elsasser A, Ritter I, Steubl D, Wanner C, Wheeler DC. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 2022 Jun 2;45(6):1445-1452. doi: 10.2337/dc21-2034. PubMed 35472672 ↗
  • Almaimani M, Sridhar VS, Cherney DZI. Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease. Curr Opin Nephrol Hypertens. 2021 Sep 1;30(5):474-481. doi: 10.1097/MNH.0000000000000724. PubMed 34074889 ↗
  • Piperidou A, Loutradis C, Sarafidis P. SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. J Hum Hypertens. 2021 Jan;35(1):12-25. doi: 10.1038/s41371-020-00393-4. Epub 2020 Aug 10. PubMed 32778748 ↗
  • Gonzalez DE, Foresto RD, Ribeiro AB. SGLT-2 inhibitors in diabetes: a focus on renoprotection. Rev Assoc Med Bras (1992). 2020 Jan 13;66Suppl 1(Suppl 1):s17-s24. doi: 10.1590/1806-9282.66.S1.17. PubMed 31939531 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Jul 2022, 41 months.

Results were first posted in Jul 2023, 1 year after primary completion.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 41 months is above that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2018
First posted
Jul 20, 2018
StartActual
Jan 31, 2019
Primary completionActual
Jul 5, 2022
CompletionActual
Jul 2, 2024
Results first posted
Jul 27, 2023
Last update
Jul 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03594110
Responsible party
Sponsor
First posted
Jul 20, 2018
Start date
Jan 31, 2019
Primary completion
Jul 5, 2022
Completion
Jul 2, 2024
Results posted
Jul 27, 2023
Last update
Jul 20, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion